AstraZeneca today announced that its partner Ironwood Pharmaceuticals, Inc. has received marketing authorisation from the National Medical Products Administration (NMPA) for Linzess (linaclotide) in China for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C)
AstraZeneca meddelar idag organisationsförändringar för att stödja fortsatt vetenskaplig innovation och kommersiell framgång inom de huvudsakliga terapiområdena, i samband med att bolaget går in i en ny fas i dess strategiska utveckling. Som en del av förändringarna meddelas att den mycket erkända onkologiforskaren José Baselga också rekryterats.
AstraZeneca today announced that the European Commission (EC) has approved Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
AstraZeneca and MSD’s Lynparza significantly improved objective response rate compared to chemotherapy in platinum-sensitive relapsed patients who had two or more prior lines of chemotherapy
AstraZeneca today announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney disease (CKD) that are either non-dialysis-dependent or dialysis-dependent, respectively.
AstraZeneca and Merck & Co. US today announced that the FDA has approved Lynparza for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.....
AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. has now received formal marketing authorisation from the National Medical Products Administration for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor and new oral treatment for patients with anaemia caused by chronic kidney disease that are on dialysis.
AstraZeneca today announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines.
AstraZeneca and MedImmune today announced overall survival results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi monotherapy or Imfinzi in combination with tremelimumab versus standard-of-care chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma......
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma (MCL).
NT-rådets (Rådet för nya terapier) rekommendation till landstingen är att Imfinzi (durvalumab) kan införas som ett behandlingsalternativ vid icke småcellig lungcancer (NSCLC). Beslutet innebär att NT rådet ser ett visst värde i behandlingsalternativet men låter landsting och regioner själva avgöra i vilken mån det ska införas som ett behandlingsalternativ.
AstraZeneca, together with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, USA, December 1-4.
AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for Fasenra (benralizumab) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA).
AstraZeneca and MedImmune, today announced final overall survival results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinzi and tremelimumab, an anti-CTLA4 antibody, versus standard-of-care platinum-based chemotherapy in previously-untreated patients with Stage IV (metastatic)NSCLC.
AstraZeneca has agreed to sell US rights to Synagis(palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction.
AstraZeneca and Merck & Co., Inc. US today announced that the US FDA has accepted a supplemental New Drug Application for Priority Review for the use of Lynparza tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
Fewer MACE events observed with Farxiga vs. placebo, but this finding did not reach statistical significance No imbalance in amputations, fractures, bladder cancer or Fournier’s gangrene with Farxiga vs. placebo
AstraZeneca återgår till tillväxt i produktförsäljningen; nya läkemedel och tillväxtmarknaderna leder vägen
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), usedfor the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines.
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III CV outcomes trial (CVOT) DECLARE-TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company’s CVRM therapy area at the American Heart Association (AHA) Scientific Sessions, 10-12 November 2018, in Chicago, Illinois, USA.